[go: up one dir, main page]

MX352871B - Método para disminuir inmunogenicidad. - Google Patents

Método para disminuir inmunogenicidad.

Info

Publication number
MX352871B
MX352871B MX2015010691A MX2015010691A MX352871B MX 352871 B MX352871 B MX 352871B MX 2015010691 A MX2015010691 A MX 2015010691A MX 2015010691 A MX2015010691 A MX 2015010691A MX 352871 B MX352871 B MX 352871B
Authority
MX
Mexico
Prior art keywords
decreasing immunogenicity
immunogenicity
decreasing
disclosed
variable domains
Prior art date
Application number
MX2015010691A
Other languages
English (en)
Inventor
Borras Leonardo
Urech David
Gunde Tea
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of MX352871B publication Critical patent/MX352871B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo de cadena única (scFv), en donde la scFv comprende una cadena ligera variable que comprende una serina en la posición 101 (numeración AHo) y una cadena pesada variable que comprende Serina (S) en la posición de la cadena pesada de aminoácido 12, Treonina (T) en la posición de la cadena pesada de aminoácido 103, y Treonina (T) en la posición de la cadena pesada de aminoácido 144 (numeración AHo).
MX2015010691A 2009-12-23 2010-12-21 Método para disminuir inmunogenicidad. MX352871B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28944609P 2009-12-23 2009-12-23
PCT/CH2010/000326 WO2011075861A1 (en) 2009-12-23 2010-12-21 Method for decreasing immunogenicity

Publications (1)

Publication Number Publication Date
MX352871B true MX352871B (es) 2017-12-13

Family

ID=43733894

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015010691A MX352871B (es) 2009-12-23 2010-12-21 Método para disminuir inmunogenicidad.
MX2012005345A MX2012005345A (es) 2009-12-23 2010-12-21 Metodo para disminuir inmunogenicidad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012005345A MX2012005345A (es) 2009-12-23 2010-12-21 Metodo para disminuir inmunogenicidad.

Country Status (17)

Country Link
US (4) US8796425B2 (es)
EP (3) EP2516461A1 (es)
JP (6) JP5914353B2 (es)
KR (3) KR101758703B1 (es)
CN (2) CN102686608A (es)
AR (1) AR079700A1 (es)
AU (1) AU2010335950B2 (es)
BR (1) BR112012017051A2 (es)
CA (1) CA2777527C (es)
CL (1) CL2012001696A1 (es)
MX (2) MX352871B (es)
PH (1) PH12012500794A1 (es)
RU (1) RU2585534C2 (es)
TW (3) TWI633184B (es)
UY (2) UY39290A (es)
WO (1) WO2011075861A1 (es)
ZA (4) ZA201202299B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101671886B1 (ko) * 2008-06-25 2016-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
EP2307458B1 (en) * 2008-06-25 2018-04-11 ESBATech, an Alcon Biomedical Research Unit LLC Humanization of rabbit antibodies using a universal antibody framework
AU2009264564B2 (en) * 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
MX352871B (es) * 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
KR20220114104A (ko) * 2011-06-23 2022-08-17 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
BR112016026773A2 (pt) 2014-05-16 2017-12-12 Ablynx Nv domínios variáveis de imunoglobulina aperfeiçoados
CN108350069B (zh) * 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
RS60823B1 (sr) 2015-12-04 2020-10-30 Boehringer Ingelheim Int Biparatopski polipeptidi koji antagonizuju wnt signalizaciju u tumorskim ćelijama
CN109689684B (zh) 2016-07-06 2022-09-23 细胞基因公司 具有低免疫原性的抗体及其用途
BR112019022729A2 (pt) 2017-05-31 2020-05-19 Boehringer Ingelheim Int polipeptídeos que antagonizam sinalização da wnt em células de tumor
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
US20250051826A1 (en) 2021-12-13 2025-02-13 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
IL316376A (en) * 2022-05-06 2024-12-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018792A1 (en) 1992-03-18 1993-09-30 Biomira Inc. Selective alteration of antibody immunogenicity
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
BR0207283A (pt) * 2001-02-19 2004-08-17 Merck Patent Gmbh Anticorpos anti-egfr modificados com imunogenicidade reduzida
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
OA13234A (en) * 2003-08-13 2006-12-13 Pfizer Prod Inc Modified human IGF-1R antibodies.
AU2008267733B2 (en) * 2007-06-25 2013-11-14 Esbatech, An Alcon Biomedical Research Unit Llc Sequence based engineering and optimization of single chain antibodies
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
US8243678B2 (en) * 2008-03-10 2012-08-14 Motorola Mobility, Inc. Hierarchical pilot structure in wireless communication systems
EP2307458B1 (en) * 2008-06-25 2018-04-11 ESBATech, an Alcon Biomedical Research Unit LLC Humanization of rabbit antibodies using a universal antibody framework
AU2009264564B2 (en) * 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
SI2307455T1 (sl) * 2008-06-25 2017-07-31 Esbatech, An Alcon Biomedical Research Unit Llc Optimizacija topnosti imunoveziv
MX352871B (es) * 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.

Also Published As

Publication number Publication date
TWI633184B (zh) 2018-08-21
RU2012130945A (ru) 2014-01-27
ZA201706443B (en) 2020-12-23
JP2015131855A (ja) 2015-07-23
KR20120102061A (ko) 2012-09-17
JP2021153603A (ja) 2021-10-07
US8796425B2 (en) 2014-08-05
JP2013515460A (ja) 2013-05-09
CA2777527C (en) 2020-06-23
CN102686608A (zh) 2012-09-19
AU2010335950B2 (en) 2014-08-21
KR20170036137A (ko) 2017-03-31
AU2010335950A1 (en) 2012-07-19
EP4219545A1 (en) 2023-08-02
UY39290A (es) 2021-07-30
TW201125975A (en) 2011-08-01
RU2585534C2 (ru) 2016-05-27
UY33154A (es) 2011-06-30
US20110152505A1 (en) 2011-06-23
US20210214461A1 (en) 2021-07-15
US10781268B2 (en) 2020-09-22
EP2516461A1 (en) 2012-10-31
AR079700A1 (es) 2012-02-15
JP2019141071A (ja) 2019-08-29
CL2012001696A1 (es) 2013-03-08
CN109293768A (zh) 2019-02-01
MX2012005345A (es) 2012-06-08
US9803027B2 (en) 2017-10-31
JP2016094487A (ja) 2016-05-26
WO2011075861A1 (en) 2011-06-30
JP5914353B2 (ja) 2016-05-11
JP6815083B2 (ja) 2021-01-20
PH12012500794A1 (en) 2012-11-26
JP2017121254A (ja) 2017-07-13
US20150080555A1 (en) 2015-03-19
ZA201402145B (en) 2018-05-30
KR101758703B1 (ko) 2017-07-18
TW201925228A (zh) 2019-07-01
BR112012017051A2 (pt) 2017-12-05
TW201619383A (zh) 2016-06-01
US20180016350A1 (en) 2018-01-18
ZA201202299B (en) 2014-06-25
KR101721187B1 (ko) 2017-03-29
EP3498731A1 (en) 2019-06-19
ZA202006532B (en) 2022-04-28
CA2777527A1 (en) 2011-06-30
TWI662128B (zh) 2019-06-11
KR20170084357A (ko) 2017-07-19

Similar Documents

Publication Publication Date Title
MX352871B (es) Método para disminuir inmunogenicidad.
HK1219741A1 (zh) 結構域抗體的生產方法
HUE051430T2 (hu) Eljárás variábilis domének elõállítására
MX2013001045A (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
IL217381A0 (en) Optimizing the production of antibodies
GB2472482B (en) Contextual voice commands
IL200919A0 (en) Methods for generation of antibodies
PL2563739T3 (pl) Sposób wytwarzania cegieł przy zastosowaniu bakterii wytwarzającej enzym
NZ621170A (en) Anti-human cd52 immunoglobulins
AU2013207589A1 (en) Anti-Siglec-15 Antibody
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
IL217919A0 (en) Humanized anti-cdcp1 antibodies
MY163339A (en) A method of producing ingenol-3-angelate
PL2553082T3 (pl) Sposób i urządzenie do wytwarzania biogazu
PT2632946T (pt) Método para a produção de domínios variáveis únicos da imunoglobulina
GB2495884B (en) A method of increasing the effect of an activated-potentiated form of an antibody
IL205051A (en) Method for producing antibodies
EP2221384A4 (en) METHOD FOR MANUFACTURING ANTIBODY
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
WO2010109185A3 (en) Process for the preparation of doxazosin and salts thereof
PL2526087T3 (pl) Sposób wytwarzania wodoronadtlenku alkilu
GB201020045D0 (en) Method for the treatment of biogas
MX2012003888A (es) Semigeles de acido silicico de superficie modificada.
MX2013002395A (es) Procedimiento de preparacion de ditiin-tetracarboximidas.